Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients

Journal of Pharmaceutical Sciences

Volumn 103, Issue 1, 2014, Pages 328-336

  Zhu, Min ^a   Doshi, Sameer ^a   Gisleskog, Per O ^b   Oliner, Kelly S ^a   Perez Ruixo, Juan Jose ^a   Loh, Elwyn ^a   Zhang, Yilong ^a  

^a AMGEN INC   (United States)

^b Exprimo NV   (Belgium)

Author keywords

cancer; clinical pharmacokinetics; hepatocyte growth factor; MET; monoclonal antibody; pharmacokinetic pharmacodynamic models; population pharmacokinetics; population pharmacokinetics pharmacodynamics; rilotumumab

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; HUMAN MONOCLONAL ANTIBODY; MOTESANIB; PANITUMUMAB; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ARTICLE; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; FEMALE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NONLINEAR SYSTEM; SEX DIFFERENCE;

CANCER; CLINICAL PHARMACOKINETICS; HEPATOCYTE GROWTH FACTOR; MET; MONOCLONAL ANTIBODY; PHARMACOKINETIC/PHARMACODYNAMIC MODELS; POPULATION PHARMACOKINETICS; POPULATION PHARMACOKINETICS/PHARMACODYNAMICS; RILOTUMUMAB;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATOCYTE GROWTH FACTOR; HEPATOCYTES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEOPLASMS; YOUNG ADULT;

EID: 84890562035     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23763     Document Type: Article

References (27)

1. Jung KH, Park BH, Hong SS,. 2012. Progress in cancer therapy targeting c-Met signaling pathway. Arch Pharm Res 35: 595-604.
2. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G,. 2012. Targeting MET in cancer: Rationale and progress. Nat Rev Cancer 12: 89-103.
3. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H,. 1999. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902.
4. Taniguchi K, Yonemura Y, Nojima N, Hirono Y, Fushida S, Fujimura T, Miwa K, Endo Y, Yamamoto H, Watanabe H,. 1998. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82: 2112-2122.
5. Burgess T, Sun J, Meyer S, Tsuruda TS, Sun J, Elliott G, Chen Q, Haniu M, Barron WF, Juan T, Zhang K, Coxon A, Kendall RL,. 2010. Biochemical characterization of AMG 102: A neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther 9: 400-409.
6. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L,. 2010. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 16: 699-710.
7. Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA,. 2011. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 13: 437-446.
8. Rosen PJ, Sweeney CJ, Park DJ, Beaupre DM, Deng H, Leitch IM, Shubhakar P, Zhu M, Oliner KS, Anderson A, Yee LK,. 2010. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 16: 2677-2687.
9. Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR,. 2013. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res 19: 215-224.
10. Schoffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F,. 2011. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int 108: 679-686.
11. Zhu M, Tang R, Doshi S, Oliner KS, Kathman S, Gisleskog PO, Dubey S, Jiang Y, Donehower RC, Iveson T, Loh E,. 2012. Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer (abstract). J Clin Oncol 30 (suppl): 2535.
12. Lorigan P, Soria J-C, Stephenson J, Maru A, Gervais R, Zhu M, McCaffery I, Jiang Y, McGreivy J, Glisson B,. 2010. Safety and pharmacokinetics of first-line AMG 479 (MAb to IGF1R) or AMG 102 (MAb to HGF/SF) with platinum-based chemotherapy in extensive-stage small cell lung cancer (SCLC) (abstract). Ann Oncol 21 (suppl 8): 444P (viii149).
13. Davidenko I, Iveson T, Donehower RC, Tjulandin S, Deptala A, Jiang Y, Zhu M, Oliner KS, Dubey S, Loh E,. 2012. Updated efficacy, biomarker, and exposure-response data from a phase 2 study of rilotumumab (R) plus epirubicin, cisplatin, and capecitabine (ECX) in gastric (G) or esophagogastric junction (EGJ) cancer. Ann Oncol 23 (suppl 9):ix230, 687P.
14. Doshi S, Kathman S Jr, Tang R, Gisleskog PO, Loh E, Dubey S, Jiang Y, Oliner KS, Donehower RC, Iveson T, Zhu M,. 2012. Modeling the combined efficacy of rilotumumab (R; AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) for the treatment of locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer (abstract). J Clin Oncol 30 (suppl): 2594.
15. Gisleskog PO, Lu JF, Perez-Ruixo JJ, Magnusson MO, Zhu M,. 2010. A mechanistic model to characterize binding dynamics of AMG 102 to HGF ligands in cancer patients. Clin Pharm Ther 87 (suppl 1): S83.
16. Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Loh E, Jiang J, Oliner KS, Dubey S,. 2011. Safety and efficacy of epirubicin, cisplatin, and capecitabine (ECX) plus rilotumumab (AMG 102) as first-line treatment for unresectable, locally advanced or metastatic, gastric or esophagogastric junction (EGJ) adenocarcinoma (abstract #446.504). Eur J Cancer 47 (suppl 1): S443.
17. Jun HT, Sun J, Rex K, Radinsky R, Kendall R, Coxon A, Burgess TL,. 2007. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 13: 6735-6742.
18. Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B,. 2007. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharm Res 24: 1910-1918.
19. Kathman S, Tang R, Doshi S, Zhu M, Hale M,. 2012. Exposure-discrete time survival analysis to assess the effect of a drug combination for gastric cancer: A case study of rilotumumab and epirubicin/cisplatin/capecitabine. Poster presented at the American College of Clinical Pharmacy Annual Meeting, Hollywood, Florida.
20. Oliner KS, Tang R, Anderson A, Lan Y, Iveson T, Donehower RC, Jiang Y, Dubey S, Loh E,. 2012. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer (abstract #4005). J Clin Oncol 30 (suppl 15).
21. Eng C, Van Cutsem E, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell EP, Davidenko I, Oliner K, Chen L, Huang J, McCaffery I, Loh E, Smethurst D, Tabernero J,. 2011. A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses (abstract #3500). J Clin Oncol 29 (suppl).
22. Hooker AC, Staatz CE, Karlsson MO,. 2007. Conditional weighted residuals (CWRES): A model diagnostic for the FOCE method. Pharm Res 24: 2187-2197.
23. Karlsson MO, Savic RM,. 2007. Diagnosing model diagnostics. Clin Pharmacol Ther 82: 17-20.
24. Jonsson EN, Karlsson MO,. 1998. Automated covariate model building with NONMEM. Pharm Res 15: 1463-1468.
25. Ette EI., 1997. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37: 486-495.
26. Dirks NL, Meibohm B,. 2010. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49: 633-659.
27. Wang W, Wang EQ, Balthasar JP,. 2008. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84: 548-558.